Liver transplant recipients with hepatitis C experienced moderate
early response rates but frequent side effects from triple therapy with
antivirals in a recent study.
Researchers evaluated 60 liver
transplant recipients with recurrent HCV genotype 1 and significant
fibrosis who underwent treatment with pegylated interferon alfa-2a and
ribavirin (PEG/RBV) and either telaprevir (TVR) (n=35) or boceprevir
(BOC) (n=25), with a minimum follow-up of 12 weeks (mean follow-up, 35
weeks). Most patients were successfully placed on immunosuppressive
therapy with cyclosporine before treatment initiation, including 33 TVR
patients and 23 BOC patients.